Peptide plasters primarily describe the product format, not the evidence of a specific mechanism of delivering the substance. This term can refer to very different technologies, including cosmetic wafers containing a peptide formulation, classic adhesive or reservoir plasters, hydrogel systems, or technologically advanced micro-needle devices designed to partially overcome the skin barrier.
Although all of these products can be described as „peptidic patches,” they can significantly differ in terms of what they actually deliver, how deeply the substance penetrates the skin, whether the peptide retains its structure, and whether its measurable amounts actually reach the systemic circulation.
The most important thing, therefore, is to distinguish between placing a product containing a peptide on the skin and demonstrating that the peptide has been delivered to a biologically relevant site.
The plaster can moisturize the skin surface, create an occlusive environment, or change its appearance without showing systemic absorption. In contrast, a properly designed micro-needle system can lead to measurable peptide concentrations in the blood, but even such a result does not automatically mean the same clinical efficacy as with an injection formulation containing the same active substance.
The broader differences between subcutaneous administration, injections, and other routes of administration have been discussed in the material „Peptide Injections and Other Routes of Administration”.
Studies have shown the systemic delivery of specific peptides using certain micro-needle systems.[1] These results are significant because they show that it is technologically possible to deliver peptides subcutaneously under certain conditions. However, the conclusions apply only to the devices, peptides, formulations, and protocols that have been tested. They cannot be automatically transferred to ordinary cosmetic patches or to any product advertised with terms such as „peptides patch” or „subcutaneous peptide delivery.”.
The evaluation of peptide patches therefore requires answering several distinct questions: What molecule is contained in the product? Where is it to be delivered? Does the patch leave the skin intact? Does it penetrate deep into the skin? Does it reach the bloodstream if systemic effects are claimed? And does the exposure obtained lead to the claimed effect?
Each of these questions represents a different level of evidence.
What exactly is a patch with peptides supposed to deliver?
First, the destination must be determined.
The first step in evaluating a peptide patch is determining where the peptide should act.
A local cosmetic claim may relate to hydration, skin surface smoothing, fine lines, or the appearance of wrinkles directly under the skin. In this case, systemic absorption may not be necessary to achieve the claimed cosmetic effect.
The local biological claim already means something different. If the proposed mechanism requires interaction with living cells located below the outermost skin barrier, the evidence should show that the appropriate amount of intact peptide reaches the appropriate layer of the skin.
The claim of systemic action requires even stronger evidence. The peptide must overcome the appropriate barriers and reach the bloodstream in a quantity sufficient to test the proposed systemic effect.
These are separate scientific questions.
The study showing a smoother appearance of the skin cannot confirm that the peptide has entered the bloodstream.
Similarly, the detection of a peptide in the blood does not prove that it improves the appearance of wrinkles, hydration, or any other local cosmetic parameter if such an effect has not also been evaluated.
For the purposes of this article, transdermal delivery primarily means transport through the skin leading to systemic exposure. However, in publications and advertising materials, the term „transdermal” is used much more broadly.
Therefore, when the term „transcutaneous” appears, the most important question is not simply whether the product came into contact with the skin.
The proper question is:
Where was the substance actually detected?
Was it only located on the surface?
Was it recovered from the stratum corneum of the epidermis?
Was it detected in deeper layers of the skin?
Did she pass through an isolated piece of skin to the receiving chamber?
Has an intact peptide also been detected in human blood?
Each of these observations represents a completely different level of evidence regarding delivery.
The amount of the ingredient is not the same as the amount delivered
The amount of peptide initially placed in the wound should not be equated with the amount that ultimately is delivered to the skin or absorbed into the body.
Between these values there are several stages.
Part of the peptide may remain trapped in the carrier layer, matrix, hydrogel, or microvial structure. Part may not release effectively enough. A certain amount may remain on the skin surface after the patch is removed. Another part may only penetrate the superficial layers of the skin, and still another may undergo degradation before reaching its target site.
Therefore, the useful product specification should distinguish between the amount placed in the system, the amount released, the amount deposited in the skin, and the amount absorbed, instead of treating these values as equivalent.
It should also specify which peptide is present in the product, what its initial amount is, how the release from the system occurs, and what evidence supports estimates regarding the actual delivery.
Statement:
„This plaster contains the peptide X”
answers the question regarding the composition of the product.
However, it does not answer the pharmacokinetic question.
This distinction is also of fundamental importance when comparing the patch with another route of administration.
Two formulations containing the same declared amount of peptide do not necessarily lead to the same biological exposure.
Therefore, the identical amount stated on the label does not prove the equivalence or interchangeability of the patch and the injection preparation.
Local effects regarding appearance have their own value
Local cosmetic effects should not be ignored just because they do not prove to be systemic.
In a randomized cosmetic study involving 52 Korean women, micro-needle systems with hyaluronic acid were compared, including a version containing acetyl hexapeptide-8. 50 participants completed the study, and the peptide-containing system showed greater improvement in wrinkle reduction at the endpoint evaluated than the micro-needle patch without the peptide. [2]
This is important evidence regarding a specific local cosmetic system.
However, the proposal should remain within the limits of this experiment.
The study did not show systemic exposure to acetyl hexapeptide-8.
It did not confirm therapeutic equivalence with the peptide administered by injection.
It also did not confirm the effectiveness of the ordinary flat adhesive patch just because it contains the same peptide.
Limiting the proposal to a local and specific formulation does not weaken the positive outcome. On the contrary—it more accurately describes what the study actually showed.
Skin barrier and molecule properties
The skin is a selective barrier
The skin is not an open membrane through which every peptide can freely penetrate.
The outer stratum corneum of the epidermis forms an important barrier to the movement of many substances. In the case of peptides, delivery can be particularly difficult, because permeability depends on the interaction of many properties of the molecule and the formulation.
The size of the molecule is important, but it is only one of the factors.
The loading, solubility in water, affinity for lipids, molecular conformation, stability, concentration, composition of the base, and the condition of the skin can all influence what happens after applying a peptide-containing product.
Therefore, statements such as „peptides do not penetrate through the skin” or „small peptides easily penetrate through the skin” are usually too simplistic.
A scientifically substantiated answer requires information about the specific peptide, formulation, skin condition, and target area.
Laboratory testing of acetyl hexapeptide-8 in emulsion clearly demonstrates the complexity of this issue. Most of the peptide used was recovered from the skin surface. Among the material detected in human skin, the largest portion remained in the stratum corneum, while in the conditions of this peptide test, neither the epidermis nor the drainage fluid contained any peptide.[3]
This is a valuable experimental result.
However, it describes the behavior of one peptide in one formulation and within one research protocol.
It should not be transformed into a universal principle regarding the permeability of all peptides or all plastids.
The formulation can change the delivery
The substrate surrounding the peptide is not merely a passive packaging.
The formulation affects the way the molecule is presented to the skin, how easily it leaves the product and how it diffuses between the formulation and the tissue.
Studies comparing emulsions containing acetyl hexapeptide-8 found differences in the delivery of the peptide to the pig skin depending on the internal structure of the formulation.[4]
The most important conclusion is not that a particular consistency of the cosmetic product automatically ensures better penetration.
The experiment, however, shows that the same peptide can behave differently when placed in different delivery systems.
Plaster introduces additional variables.
The material from which it is made can affect occlusion and hydration.
The degree of contact with the skin can affect the release of substances.
The matrix or reservoir can determine the rate at which the peptide is released.
The moisture environment under the film can also affect both the formulation and the skin barrier.
These properties should therefore be evaluated for the finished patch, and not predicted solely based on the name of the peptide.
Stability is part of the exposure problem
Delivery does not only concern where a measurable signal appears.
The peptide must also remain sufficiently intact for the proposed biological interpretation to be meaningful.
The detection of a fluorescent marker, an analytical signal, or a fragment of a molecule is not always equivalent to the detection of the original, intact peptide.
The peptide can undergo enzymatic or chemical degradation, while a portion of its signal remains detectable.
Therefore, when it is relevant to the claimed substance, analytical methods should be able to distinguish the appropriate molecule from degradation products, fragments, or interfering substances.
Studies on methods for assessing the stability of cosmetic peptides in the presence of proteases show why the fate of the molecule is part of the delivery issue.[5]
Such laboratory methods can improve the stability characteristics of the peptide.
However, they do not independently prove the clinical effectiveness of the ready-made patch.
More information about why the stability of a peptide depends on formulation, temperature, humidity, packaging, and other conditions is presented in the article „Storage of Peptides”.
A stronger question regarding delivery therefore sounds like this:
What amount of intact peptide reaches the target site, how long does it remain there, and how repeatable is this exposure between consecutive applications and different individuals?
Microscopic images and other visualization methods can help answer this question.
However, they constitute only one element of a complete set of evidence.
Adhesive patches and micro-needle systems
Classic adhesive and hydrogel patches
A classic flat patch can keep the formulation in contact with the skin for a longer period of time.
This can create a local environment different from the situation where the cream is simply applied to the skin and left uncovered.
The material itself of the patch can increase hydration through occlusion, prolong the contact of the formulation with the skin, or change the way the ingredients are distributed in the application area.
As a result, the patch itself may contribute to the observed effect.
If researchers want to determine whether a particular peptide is responsible for the cosmetic effect, it is best to compare the patch containing the peptide with an appropriately matched patch that is identical in all other respects but does not contain the peptide.
Comparison of a complete patch with a peptide alone with untreated skin does not allow to separate the effect of the peptide from the effect of hydration, occlusion, carrier material, and other components of the formulation.
The absence of needles does not automatically mean that the delivery of the substance is impossible.
However, it means that any claim regarding a significant skin barrier crossing requires evidence relating to the specific technology used for passive or assisted delivery.
Microneedles deliberately change the problem of skin barrier
Micro-needle systems approach the delivery of peptides in a different way.
Instead of relying solely on passive penetration through the intact stratum corneum, they use very small protrusions designed to overcome at least part of the outer barrier of the skin.
Different micro-needle technologies work in different ways.
In some devices, the active substance is located on the surface of the microvias.
Others use dissolvable tabs that release the material contained within them when introduced.
Others use more complex technological structures.
Geometry, material, mechanical strength, penetration repeatability, peptide formulation, and the method of application can all influence the performance of the system.
Therefore, the micro-needle patch differs scientifically from the classic flat cosmetic sheet.
Two products can contain the same peptide and at the same time exhibit completely different delivery capabilities due to the use of different skin contact technologies.
Similarly, evidence regarding a single microinjector platform cannot automatically confirm the performance of another platform made from different materials or using different dimensions and release properties.
In a human pharmacokinetic study involving the parathyroid hormone fragment, the plasma concentration profile of the compound was measured after administration using a coated micro-needle system.[1]
This is a much stronger evidence of systemic delivery than the mere assumption that absorption occurs because the person was wearing a patch.
Other assisted delivery systems are separate technologies.
Microneedles are not the only method used to overcome the skin barrier.
Some experimental systems use electric power to assist transportation.
In a study using isolated human skin, peptide transport during ionophoresis differed depending on the molecule’s properties and formulation.[6]
This result applies specifically to the electrically assisted system.
It should not be attributed to the usual adhesive plaster.
Similarly, the experimental conditions used in controlled studies of ionophores should not be converted into instructions for self-administration.
The operation and safety of such technology depend on the complete system, including electrical parameters, formulation properties, skin condition, and the device design.
| System | The main question that requires investigation | What cannot be assumed without evidence |
|---|---|---|
| Flat cosmetic plaster | Local action of the entire formulation and carrier | Systemic absorption of the peptide |
| Beer tank plaster | Release and passage through intact skin | Appropriate exposure based solely on the amount placed in the plaster |
| Micro-needle system | Recurrent penetration, release, exposure and tolerance | The equivalence of different devices |
| Electrically assisted system | The actions of the formulation together with the electrical system | The same action without the element of assistance in delivery |
The table shows why the „peptid plaster” should not be treated as a single scientific category. The mechanism, appropriate measurements, and the required level of evidence vary significantly between different technologies.
Measurement of delivery and systemic exposure
Laboratory studies evaluate the individual stages
Various laboratory experiments answer different parts of the delivery question.
The release study assesses whether and at what rate the peptide leaves the formulation or delivery system.
The study of deposition in the skin allows determining the amount of material that is bound to the individual layers of the skin.
The permeation test assesses whether the substance passes through the skin sample and appears in the receiving chamber on the opposite side of the skin.
These experiments are related to each other, but they are not equivalent.
For example, stripping tape can help in examining material located in the outer layers of the skin.
The diffusion chamber experiment can assess transport through a skin sample under controlled laboratory conditions.
None of these experiments alone determines the blood concentrations that would occur in a person wearing a ready-made patch.
The interpretation must also take analytical limitations into account.
The integrity of the skin sample can affect permeability.
The sampling procedures can affect the recovery of material.
The analytical method has a defined detection limit.
The mass balance may be incomplete.
Therefore, the statement that a peptide „was not detected” usually means that under the conditions of the experiment the method did not detect a quantity exceeding the applicable detection limit.
It should not be automatically interpreted as universal proof that no molecule can ever and under any conditions cross the skin barrier.
The pharmacokinetics in humans measures exposure over time
Pharmacokinetic studies in humans provide a stronger basis for assessing systemic delivery because they directly measure human exposure.
Instead of relying on a single blood sample, pharmacokinetic studies typically use a series of samples taken at different time points.
This allows to characterize several aspects of the exposure.
One of the important parameters is the maximum concentration, often referred to as Cmax.
The next step is the time required to reach that maximum.
Researchers can also calculate the area under the concentration-time curve, known as the AUC, which describes the total systemic exposure over the analyzed period.
These parameters answer various questions.
Two delivery systems can lead to similar total exposure, but very different maximum concentrations.
The other two systems can achieve similar maximum concentrations at different times.
A single blood sample could easily overlook these differences.
In an early study of the microstructural system for subcutaneous administration of abaloparatide, 22 postmenopausal women participated. The systemic exposure was evaluated during repeated administration, while local reactions at the application site were also recorded. [7]
The study provided evidence confirming the feasibility of applying this specific experimental system.
Early demonstration of the ability to deliver and determine the pharmacokinetics does not, however, resolve all subsequent questions regarding comparative efficacy, long-term safety, or therapeutic equivalence.
Absorption and clinical equivalence are different stages of evidence
Demonstrating that the peptide reaches the bloodstream is an important scientific achievement.
However, it is not the final stage of proving that the patch works as well as the established treatment method.
In a six-month randomized study involving 165 postmenopausal women, a teriparatide patch was evaluated and bone mineral density was analyzed compared to placebo and a preparation administered by injection. [8]
The study went beyond a simple assessment of delivery, as it analyzed a clinically relevant research point.
However, even the result regarding bone mineral density should not be automatically converted into evidence of fracture prevention, regulatory approval, or the effectiveness of another patch containing a peptide.
The difference between effective absorption and adequate clinical efficacy becomes particularly evident in later studies of abdominal aortic aneurysm.
In a Phase III study involving 511 participants, both the microstructural subcutaneous system and the injection increased bone mineral density in the lumbar spine segment. However, the subcutaneous system did not previously meet the established non-inferiority criterion compared to the injection. [9]
This result shows an important principle:
„The peptide was absorbed” and „the patch achieved an appropriate result compared to the reference treatment” are two separate scientific statements.
Previous results regarding the delivery or feasibility of technologies cannot substitute for later results of comparative clinical trials.
Local cosmetic endpoints do not measure systemic delivery
Studies of cosmetic micro-needle systems provide another good example of why individual endpoints should be considered separately.
In a multicomponent micro-needle patch containing hyaluronic acid, changes were observed regarding hydration, wrinkles, and skin parameters evaluated using imaging methods.[10]
These observations apply to the finished local cosmetic formulation.
Because the patch contained several peptide and non-peptide components, the study does not need to indicate which specific component was responsible for the observed change.
More importantly, measurements of hydration, wrinkles, or local skin imaging properties do not indicate the achievement of a clinically significant concentration of the peptide in the blood.
Cosmetic research should not therefore be considered a pharmacokinetic study simply because the delivery technology used penetrates or partially bypasses the skin barrier.
Validation of a specific product
Identity, liberation, exposure and effect must be combined
A convincing set of evidence should follow the same finished product through a logical series of questions.
First of all, has the peptide been correctly identified and is it sufficiently stable?
Secondly, does the delivery system release it in a repeatable manner?
Thirdly, where does the peptide go after it is released?
Fourthly, is the exposure obtained repeatable?
And finally, does the entire product produce the declared effect with acceptable tolerance?
These questions form a chain of evidence.
Evidence from one stage cannot automatically fill the gap in another.
Each result should remain linked to the formulation, device, population, and experimental conditions that were actually studied.
The entire activity of a single product cannot be confirmed by a compilation of independent studies in which the same peptide was present in completely different delivery forms.
The choice of comparator is also important.
A version of the same patch without the peptide can help determine whether the peptide adds an additional effect beyond the effect of the carrier and the application conditions.
Comparison with an active medicinal product answers another question: how does the experimental system perform compared to the established treatment method.
The photo of untreated skin cannot replace any of these controlled comparisons.
Evidence of delivery does not determine the regulatory status
Scientific research and regulatory approval are separate issues.
The publication showing the delivery of the peptide in itself does not mean that the product has been approved.
The patent also does not mean that.
Similarly, registration of a clinical trial does not mean that the product under investigation has received a marketing authorization.
If a claim regarding a medicinal product appears, the regulatory status of the specific product, formulation and route of administration should be checked in the relevant official register.
For example, the European Medicines Agency documentation regarding Forsteo describes the therapeutic product containing teriparatide intended for injection. [11]
Such an authorization does not automatically include a transdermal patch simply because it contains teriparatide.
Similarly, a cosmetic patch does not become an approved drug because one of its ingredients is chemically linked to a therapeutic peptide.
Regulatory differentiation is also important in the case of cosmetics.
The FDA distinguishes cosmetics and medicines, among other things, based on intended use and appropriate legal criteria. Ordinary cosmetics do not generally undergo FDA approval before being placed on the market, with the specific exception of color additives.[12]
However, the regulatory framework itself should not be interpreted as evidence in favor of or against the effectiveness of transdermal delivery of peptides.
They answer another question.
Tolerance and repeatability are part of validation
The effectiveness of delivery is only one of the elements of the plaster assessment.
The tolerance in the actual application site should also be evaluated.
In the case of adhesive systems, this may include reactions related to the material of the patch, prolonged contact and repeated exposure.
In the case of microelectrodes or other advanced systems, researchers can additionally assess local responses to the device, the accuracy of penetration, and failed applications.
The statement that no serious adverse reactions occurred in a small study does not prove universal safety.
The number of participants, the duration of the exposure, and the types of events monitored determine the scope of conclusions that can be reasonably drawn.
The repeatability of the product’s properties does not end even on the day of production.
The packaging and storage conditions are important because the evidence should refer to the entire declared shelf life of the product.
The plaster that still appears physically intact does not necessarily retain the same peptide concentration, chemical stability, or release characteristics.
The most justified claim therefore remains product-specific.
Some advanced peptide delivery systems have shown measurable delivery in humans.
However, many broader consumer claims regarding systemic absorption, therapeutic equivalence, and overall efficacy of „transdermal peptides” remain unconfirmed until a specific product has been properly tested.
Frequently asked questions
1. Does wearing the patch itself prove the absorption of the peptide?
No. Wearing a patch merely demonstrates that the product remained in contact with the skin; it does not confirm the delivery of the peptide to a specific layer of the skin or into the bloodstream. In microgel studies in humans, systemic delivery was evaluated by measuring the concentration of the peptide, not by assuming that absorption occurred solely because a patch was applied. [1] Similarly, a local change in moisture, smoothness, or skin appearance does not replace the missing pharmacokinetic data. A reliable claim of absorption should specify which molecule was detected, whether it remained intact, where it was measured, when the measurements were taken, and what analytical method was used. The contact with the skin is therefore the beginning of the question of delivery, not evidence that it occurred.
2. Are all peptide patches transdermal drugs?
No. Products labeled as peptide patches may belong to very different categories. Some are cosmetics intended to have a local effect on the appearance of the skin, while others are experimental or therapeutic delivery technologies intended to provide systemic exposure. The regulatory framework for cosmetics and medicines therefore addresses different questions. [11][12] An injection product containing a specific peptide does not automatically confer the status of a medicinal product to a patch containing the same active substance. Determining status requires examining the precise product, route of administration, indication, and jurisdiction, rather than relying on general terms such as „peptide” or „patch”.
3. Is skin penetration the same as systemic absorption?
No. A peptide can migrate from the formulation to the superficial layers of the skin, never reaching the bloodstream. In the acetyl hexapeptide-8 study, material remaining on the skin surface, material detected in the skin layers, and material reaching the drainage fluid were distinguished.[3] These are different endpoints. Systemic exposure requires evidence of blood flow and should usually include changes in concentration over time. An image of penetration or measurement of deposition in the skin can therefore provide valuable local information without requiring independent confirmation of systemic activity.
4. Can a cosmetic plaster moisturize the skin without showing the delivery of a peptide?
Yes. The plaster can improve hydration through the local action of the formulation, occlusion, and prolonged contact with the skin without showing significant absorption of the peptide. In cosmetic studies, microparticles were evaluated for hydration and wrinkle appearance, but these points relate to the local cosmetic effect and not the overall pharmacokinetics. [2] The plaster material, hyaluronic acid, and other components of the formulation may also be important. Therefore, real improvement in hydration can be described without claiming that it indicates the overall delivery of the peptide or a mechanism characteristic of the drug.
5. Does the dissolution of microgels prove the complete delivery of the peptide?
No. The disappearance or dissolution of the micro-aggregate structure does not independently determine the amount of intact peptide deposited in the tissue and subsequently absorbed. In microstructural studies of peptide systems in humans, systemic exposure is still directly measured. [7] Part of the active substance may remain close to the surface, be unevenly distributed, undergo degradation, or fail to reach the bloodstream. Therefore, the visual disappearance of the plaques is not equivalent to a complete mass balance. Valid claims about delivery require analytical data regarding the finished system.
6. Does a higher amount of peptide in the patch mean proportionally higher exposure?
Not necessarily. The amount initially placed in the patch, the amount released, the amount transported through the skin, and the amount remaining intact are separate values. Studies of peptide transport show that formulation properties and delivery conditions can significantly influence permeability.[6] Therefore, doubling the amount declared on the label does not necessarily lead to a doubling of overall systemic exposure. The relationship between the patch content and actual exposure must be determined experimentally for a specific product.
7. Can a patch replace an injection containing the same peptide?
Interchangeability cannot be assumed. A change in the route of administration and the delivery technology can affect the time to reach a concentration, the maximum concentration value, total exposure, variability, and the clinical effect of the active substance. The phase III study of abaloparatide well illustrates this difference: although both the microstructural system and the injection increased bone mineral density in the lumbar spine segment, the transcutaneous system did not demonstrate non-inferiority to the injection in the previously established main comparison. [9] The mere presence of the same active substance therefore does not constitute sufficient evidence of interchangeability of formulations.
8. Does the improvement of wrinkles after cosmetic surgery indicate systemic action?
No. The improvement in the appearance of wrinkles at the application site is a local cosmetic endpoint. It does not confirm a measurable concentration of the peptide in the blood or activity in other parts of the body. In the cosmetic patch study, the appearance of the skin and related local parameters in the area treated with the product were evaluated. [2] These results remain valuable in this context. Claims of systemic effects would require additional pharmacokinetic data and, when applicable, clinical studies specifically designed to assess the proposed systemic effect.
9. Does the positive laboratory result of penetration prove that the patch works in humans?
No. Laboratory skin models can demonstrate important stages of the delivery process, but they do not replicate all the properties of live human skin, circulation, metabolism, or actual application conditions. Studies of formulations containing acetyl hexapeptide-8 show how delivery can change under controlled experimental conditions.[4] Such results may support product development and understanding of the mechanism. Effectiveness in humans still requires appropriate studies measuring exposure and the intended effect.
10. Will the smaller peptide definitely penetrate through the skin?
No. The size of the molecule affects transport through the skin, but it is only one of many important factors. Charge, hydrophilicity, affinity for lipids, molecular structure, stability, concentration, the composition of the vehicle, and the condition of the skin can also influence delivery. In transport studies, many variables are analyzed precisely because no single molecule property determines the entire result. [6] A relatively small molecular weight may be interesting from a formulation standpoint, but it does not prove that the finished product delivers clinically relevant amounts of the substance to the target site.
11. Can the fluorescent image prove that the intact peptide has reached its target?
Not independently. Fluorescence can show the location of the detectable signal, but it does not necessarily mean that a complete and chemically intact original peptide remains at that location. The fluorescent marker or detectable fragment may remain present even after changes in the molecule. Studies of the stability of cosmetic peptides show why the chemical characterization still matters. [5] Imaging and analytical chemistry can complement each other, but the bright signal on the image alone does not prove the delivery of an intact and functional peptide.
12. Does the successful Phase I study regarding delivery confirm the effectiveness of the treatment?
No. Early clinical studies can demonstrate the feasibility of the delivery technology, characterize the pharmacokinetics, and provide preliminary information on tolerability. However, they do not need to answer the question of whether the system leads to appropriate clinical outcomes compared to established treatment. The early study of the microstructural system with abaloparatide justified further development of the technology, whereas the later, larger Phase III study addressed a much more demanding comparative question. [7][9] These stages should be distinguished. A positive early result regarding delivery does not mean that all subsequent questions about efficacy, safety, and regulatory approval have already been resolved.
13. Are all micro-needle patches equivalent?
Micro-needle technologies can vary in material, geometry, length of the protrusions, mechanical strength, peptide arrangement, dissolution method, and application method. The human studies and cosmetic studies discussed concerned specific systems rather than a single interchangeable class of devices.[1][10] Even patches that look similar or contain the same peptide can therefore lead to different delivery profiles. Each product requires evidence regarding its own design, formulation, and intended effect, especially when the claims go beyond local cosmetic effects.
14. Does the absence of irritation prove that the patch is safe?
No. The results regarding tolerance are limited by the number and characteristics of the participants, the timing of administration, and the types of events monitored by the researchers. In early studies of systemic delivery systems, responses at the site of administration were recorded, which shows why local effects are part of the assessment of the patch. [7] On the other hand, a small study in which no serious reactions occurred cannot rule out rare events that only appear in a larger population. Claims regarding safety should therefore describe the data actually collected, and not treat good tolerance in a limited study as a universal guarantee.
15. Can the study of a multi-component patch prove that the peptide was responsible for the effect?
No, unless the study design adequately separates the involvement of the peptide from the activity of the other components. A patch containing several potentially active substances may show that the entire formulation produced a specific effect, while leaving uncertainty about the involvement of each component. A study of a multi-component micro-needle system illustrates this distinction well. [10] A patch devoid of the peptide could provide stronger evidence of the independent involvement of the peptide. Without such a comparison, the conclusion should apply to the tested combination and the specific endpoint.
16. Does the approval of the injectable peptide also include its version in plaster?
No. Regulatory approval applies to a specific medicinal product of a specific formulation, route of administration, indication, and set of evidence. For example, the EMA documentation regarding Forsteo refers to a specific medicinal product containing teriparatide intended for injection. [11] Such approval cannot simply be transferred to a patch containing teriparatide. The proposed patch requires evaluation in accordance with the scientific and regulatory requirements specific to this product. Experimental publications, patents, or comparisons presented by online retailers do not replace the official product approval entry.
17. What are the strongest evidence to look for in the case of the peptide patch?
The strongest evidence links a precisely defined ready-to-use patch with a repeatable delivery and a specific declared effect. In the case of general systemic claims, this usually means data confirming the identity and stability of the peptide, repeatable release from the device, human pharmacokinetic exposure, and relevant controlled clinical results. In the case of local cosmetic claims, appropriate comparisons and measurements should assess the finished formulation and the area of application. The transition from early studies of abaloparatide delivery to later comparative studies illustrates why both exposure and effect data are important. [7][9] The regulatory status should then be verified independently, since effective scientific research and formal product approval are two separate matters.
Summary
Peptide patches should not be considered as if they were a single, uniform delivery technology.
The classic adhesive plaster patch, the passive reservoir system, the dissolvable micro-needle platform, and the device that uses electrical stimulation approach the skin barrier in fundamentally different ways. Therefore, the requirements for evidence are also different.
The most important thing is to distinguish between presence, release, penetration, systemic absorption, and the clinical effect.
The presence of the peptide in the plaster confirms its composition.
The release of the peptide from the patch shows that at least part of the substance can leave the formulation.
Its detection in the superficial layers of the skin confirms local deposition.
The passage through a skin sample in a laboratory study provides evidence of penetration under the conditions of the experiment.
The detection of an intact peptide in human blood provides a significantly stronger level of evidence for systemic delivery.
Even then, measurable systemic exposure does not automatically prove clinical equivalence with another route of administration.
Studies of micro-needle peptide technology demonstrate this progression of evidence well. Pharmacokinetic studies in humans have shown that certain advanced systems can deliver peptides systemically. [1][7] Subsequent clinical studies then evaluated whether these systems lead to the desired effects. A later comparison of abaloparatide is particularly instructive because the systemic delivery itself did not automatically translate into demonstrating non-inferiority to injections. [9]
Peptide cosmetic patches also require careful interpretation, although their intended action may be local rather than systemic. The patch can improve hydration, the appearance of wrinkles, or other cosmetic endpoints without demonstrating significant exposure in the blood. Such local results remain scientifically valuable if they are described within the appropriate range.
The formulation is also important. The size of the molecule itself does not allow predicting delivery. The composition of the substrate, the stability of the peptide, the structure of the film, the skin condition, the release characteristics, and the applied adjuvant technology can all influence what actually reaches the target site.
Therefore, evidence should always be linked to a specific peptide, a ready-made formulation, device, application conditions, the study population, and the endpoint being evaluated.
The study of a single micro-needle technology cannot confirm the effectiveness of all micro-needle patches.
Laboratory penetration testing cannot independently confirm systemic exposure in humans.
Local improvement in the appearance of wrinkles does not indicate an effect on the entire body.
The marketing of the peptide in the form of an injection preparation does not automatically include a patch containing the same active substance.
The most justified assessment should therefore follow the evidence step by step: identify the molecule, characterize its stability, demonstrate release, determine where the intact substance goes, measure systemic exposure if declared, assess the intended effect, examine tolerance, and separately verify the regulatory status.
Simply wearing a patch with peptides does not prove the absorption of the peptide.
Similarly, the smoother appearance of the skin, the detection of a peptide-related signal in superficial tissues, or the existence of an approved version of the same peptide intended for injection do not confirm the delivery of systemic, therapeutic equivalence, nor regulatory approval of the patch.
Disclaimer
This article is for educational and scientific informational purposes only. It discusses research on peptide patches, delivery through the skin, micro-needle technology, pharmacokinetics, cosmetic effects, and product verification. It does not constitute a recommendation regarding the use of any peptide patch, drug product, or delivery device. It also does not contain instructions for application, dosage, administration, or replacement of one route of administration with another.
Evidence from laboratory skin models, diffusion experiments, microfluidic studies, or early clinical studies refers to the specific molecule, formulation, device, and experimental conditions that were actually evaluated. Results from such studies should not be automatically extrapolated to other patches simply because they contain the same peptide or use similar terms.
Similarly, evidence that the peptide reaches the bloodstream does not independently confirm therapeutic efficacy, equivalence to injection, long-term safety, or regulatory approval.
Clinical and regulatory claims should be verified for the specific finished product and the relevant jurisdiction. The examples of studies discussed in this article serve to explain how to interpret evidence regarding the delivery of peptides and should not be treated as individual medical, cosmetic, or therapeutic advice.
References
- Daddona, P. E., Matriano, J. A., Mandema, J., & Maa, Y. F. (2011). Parathyroid hormone (1-34)-coated microneedle patch system: Clinical pharmacokinetics and pharmacodynamics for the treatment of osteoporosis. Pharmaceutical Research, 28(1), 159–165. https://doi.org/10.1007/s11095-010-0192-9
- An, J. H., Lee, H. J., Yoon, M. S., & Kim, D. H. (2019). Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin. Annals of Dermatology, 31(3), 263–271. https://doi.org/10.5021/ad.2019.31.3.263
- Kraeling, M. E., Zhou, W., Wang, P., & Ogunsola, O. A. (2015). In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutaneous and ocular toxicology, 34(1), 46–52. https://doi.org/10.3109/15569527.2014.894521
- Hoppel, M., Reznicek, G., Kählig, H., Kotisch, H., Resch, G. P., & Valenta, C. (2015). Topical delivery of acetyl hexapeptide-8 from different emulsions: Influence of emulsion composition and internal structure. European Journal of Pharmaceutical Sciences, 68, 27–35. https://doi.org/10.1016/j.ejps.2014.12.006
- Errante, F., Menicatti, M., Pallecchi, M., Giovannelli, L., Papini, A. M., Rovero, P., & Bartolucci, G. (2021). Susceptibility of cosmeceutical peptides to proteases activity: Development of dermal stability test by LC-MS/MS analysis. Journal of Pharmaceutical and Biomedical Analysis, 194, Article 113775. https://doi.org/10.1016/j.jpba.2020.113775
- Krishnan, G., Roberts, M. S., Grice, J., Anissimov, Y. G., Moghimi, H. R., & Benson, H. A. (2014). Iontophoretic skin permeation of peptides: An investigation into the influence of molecular properties, iontophoretic conditions and formulation parameters. Drug Delivery and Translational Research, 4(3), 222–232. https://doi.org/10.1007/s13346-013-0181-8
- Miller, P. D., Troy, S., Weiss, R. J., Annett, M., Schense, J., Williams, S. A., & Mitlak, B. (2021). Phase 1b evaluation of abaloparatide solid microstructured transdermal system (abaloparatide-sMTS) in postmenopausal women with low bone mineral density. Clinical Drug Investigation, 41(3), 277–285. https://doi.org/10.1007/s40261-021-01008-7
- Cosman, F., Lane, N. E., Bolognese, M. A., Zanchetta, J. R., Garcia-Hernandez, P. A., Sees, K., Matriano, J. A., Gaumer, K., & Daddona, P. E. (2010). Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. The Journal of Clinical Endocrinology & Metabolism, 95(1), 151–158. https://doi.org/10.1210/jc.2009-0358
- Lewiecki, E. M., Czerwinski, E., Recknor, C., Strzelecka, A., Valenzuela, G., Lawrence, M., Silverman, S., Cardona, J., Nattrass, S. M., Binkley, N., Annett, M., Pearman, L., & Mitlak, B. (2023). Efficacy and safety of transdermal abaloparatide in postmenopausal women with osteoporosis: A randomized study. Journal of Bone and Mineral Research, 38(10), 1404–1414. https://doi.org/10.1002/jbmr.4877
- Avcil, M., Akman, G., Klokkers, J., Jeong, D., & Çelik, A. (2020). Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. Journal of Cosmetic Dermatology, 19(2), 328–337. https://doi.org/10.1111/jocd.13009
- European Medicines Agency. (n.d.). Forsteo. Retrieved September 25, 2026, from https://www.ema.europa.eu/en/medicines/human/EPAR/forsteo
- U.S. Food and Drug Administration. (n.d.). FDA authority over cosmetics: How cosmetics are not FDA-approved, but are FDA-regulated. Retrieved September 25, 2026, from https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated